Success for JDRF is defined by the availability of affordable life changing therapies that improve the lives of people with or at risk of T1D. These products may also have the potential to impact broader populations, such as people with insulin requiring T2D or other autoimmune diseases. Success for the JDRF research and development pipeline depends on a diversified but balanced portfolio that includes academic and industry efforts that can successfully transition from early discovery to clinical trials and product development. JDRF allocates funding and non-funding resources to ensure clinical impact and accelerated therapeutic advancements by funding projects ranging from those that are relatively close to the clinic to those that are earlier in development, such as efforts in discovery and preclinical development with potential for significant advancement and impact in longer timeframes. Taken together, these will drive progress on our mission.